N-PORT filing recap · October 2025

What did ARK Genomic Revolution ETF buy in October 2025?

Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.

Stock value

$1.31B

Positions

Estimated turnover

16.2%

Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.

Period in review

ARK Genomic Revolution ETF opened new positions in Exact Sciences Corporation and Genedx Holdings Corp. It substantially trimmed Guardant Health while adding to Arcturus Therapeutics Holdings and Ataibeckley Inc. The fund also increased Personalis, Illumina, and Caris Life Sciences, and reduced Natera, Adaptive Biotechnologies, Ionis Pharmaceuticals, and Amgen.

New positions

EXASExact Sciences Corporation$22.00Mreported value+340.0K shares WGSGenedx Holdings Corp.$14.31Mreported value+104.5K shares

Increased positions

PSNLPersonalis, Inc.$76.47Mreported value+929.4K shares+13.3%TWSTTwist Bioscience Corporation$69.30Mreported value+3.0K shares+0.1%ILMNIllumina, Inc.$48.61Mreported value+93.4K shares+31.1%TXG10x Genomics, Inc.$44.65Mreported value+11.0K shares

Reduced positions

TEMTempus Ai, Inc.$133.46Mreported value-87.6K shares-5.6%CRSPCrispr Therapeutics AG$114.76Mreported value-99.6K shares-5.3%GHGuardant Health, Inc.$64.52Mreported value-450.7K shares-39.4%RXRXRecursion Pharmaceuticals, Inc.$63.14Mreported value-81.5K shares